Grifols SA to Announce A Transformational Investment in Biotest AG Call Transcript
And very good commercial footprint, very complementary to Grifols in the sense that they are not present in the U.S., we are very strong. And they have a stronger presence in some regions in the EMEA region, which is extremely complementary, both companies.
Brief description of Biotest number. This is public data, so I will not extend much. I have said, and Raimon have said, it's a family origin company founded in 1946. They have 2 manufacturing sites, one already for many years working around 1.5 million liters of plasma per year that it can process. And just -- it's about to finish an expansion of a new plant in the same site for additional 1.5 million liters. So in total, this new combination will give 3 million liters of additional manufacturing plasma throughput capacity per year, plus the 26 centers that I have just mentioned. And last, of course, but not least, Biotest, it's an entity that around -- has around 2,000 employees overall. And you see here the projections. The last actual data for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
